Drug checking results - KYSNZ and DISC

Substance presumed to be: Methamphetamine

Date brought in for testing: Second week of September, 2004

Substances detected in the sample: Methamphetamine, possible presence of MDMA

Our in-clinic testing methods detected Methamphetamine in this sample, and suggested that there may also be MDMA present. Our strip tests did not detect any fentanyl, benzodiazepine or nitazene type drugs in this sample.

We have sent this sample to the laboratory for further analysis and we recommend waiting until these results are back before deciding whether to take this substance. If this was your sample, you can return to the Drug Checking clinic you attended to check whether we've heard back, and for additional advice to keep you and your community safer. 

If more than one drug is present, we are unable to determine how much of each drug was in this sample. If someone chooses to take this substance, we recommend starting with a lower dose than may be indicated (e.g. a half or quarter), allowing 30-60 mins for the drug to take effect, and seeing how you feel before taking more. Combining more than one stimulant is more stressful for your body, and creates greater risk of negative side effects and overdose.

You can find more information on staying safer when taking Methamphetamine here and for MDMA here.

Contact: DISC Drug Checking team [drugchecking@nznep.org.nz]

UPDATED RESULT:

Laboratory analysis has confirmed this sample was consistent with containing Bromazolam. 

Bromazolam is a novel benzodiazepine. Novel benzodiazepines, those that have entered the drug market relatively recently, are less well understood than prescription benzos or those that have been on the market for longer, such as alprazolam (Xanax). Dosing information is relatively untested and may be similar or lower than alprazolam, however there are indications that it may stay in your system for twice as long (more than 12 hours), even you no longer feel the effects. 

We are unable to determine how much of the drug may be present in this sample. As the substance may not be evenly mixed, the relative proportions of each substance may be different each time. If someone does choose to take this substance, please read the advice in below and in the links provided. Take a smaller dose than may be indicated (e.g. a half or quarter dose), allow 45-60 minutes for the drug to take effect, and see how your body feels before taking more. Make sure you or someone you are with knows the signs to look out for in case of overdose.

INITIAL RESULT:

Substance presumed to be: Alprazolam

Date brought in for testing: Second week of August, 2024

Substances detected in the sample: Possible presence of a benzodiazepine (results inconclusive).

Due to the format of this sample were unable to conduct a full analysis in-clinic, and this sample is currently at the laboratory for further analysis. We'll update this result when results arrive back. If this was your sample, you can return to the Drug Checking clinic you attended to check whether we've heard back, and for additional advice to keep you and your community safer.

Our in-clinic testing indicated a positive strip-test result for a benzodiazepine, with negative strip-test results for nitazene and fentanyl. However, benzo strip-tests react with several benzodiazepines and cannot specify which of these is present. Equally, strip-tests do not detect all types of nitazenes, especially as new nitazenes entered the drug market regularly. We recommend waiting until the result of laboratory analysis are posted before taking this substance.

Overdose is much more likely if this drug is combined with other depressants: High or repeated doses of this substance, or combination with other benzodiazepines, opioids, dissociatives, fantasy-type (G/1,4-BD) drugs or alcohol greatly increases risks of vomiting, stopping breathing, or death.

There is no overdose reversal agent available for first-aid in case of benzodiazepine overdose (naloxone will not work for this drug class) - medical care is required to ensure someone stays safe and breathing after an overdose. This may look like: slurred speech, severe confusion, delusions, slowed, shallow or stopped breathing, blue fingertips or lips, loss of consciousness. Call 111 immediately to seek medical support. 

For more information on staying safer when taking benzodiazepines click here, and for more specific information about novel benzos click here.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz

UPDATED RESULT 

Laboratory analysis has confirmed this sample was consistent with containing Alpha D2PV and eutylone. 

If this was your sample, please feel welcome to return to the Drug Checking clinic you attended for additional advice to keep you and your community safer.

INITIAL RESULT 

Substance presumed to be: MDMA

Date brought in for testing: Third week of August, 2024

Substances detected in the sample: Alpha D2PV and eutylone

Our in-clinic testing detected the presence of Alpha D2PV and eutylone in this sample. It has been sent to the laboratory for further analysis to confirm these initial results, and we’ll update this result once we have the results of that analysis. 

Alpha D2PV and eutylone are both types of synthetic cathinones, a class of stimulant drug. We are unable to determine how much of each substance is in this mixture.

Alpha D2PV is much more potent than MDMA, with a common dose of around 5-15 mg (a common dose of MDMA is 80-120 mg). This cathinone produces a strong, short-lived stimulant effects and at high doses adverse effects can include agitation, paranoia, mania, a racing heart, and hallucinations. Alpha D2PV and related substances have been implicated in harm including deaths internationally, especially when used in combination with other substances and/or when it is misrepresented (e.g. as MDMA or as a less potent cathinone). You can read more about Alpha D2PV here: Alpha-PVP like substance misrepresented as MDMA in Christchurch :: High Alert

Eutylone is also active at a lower doses than MDMA, with a common dose of around 40-80 mg (around half that of MDMA). Eutylone's effects are often described as being similar of MDMA, but with a shorter duration and less euphoric effects. This often leads people to want to take more (redose) which makes it easy to overdose, especially if they are expecting MDMA-like effects. 

Side effects from these substances – especially at higher doses – can include insomnia, anxiety, hallucinations, psychosis, paranoia, unusual/fast heartrate, overheating, tremors, convulsions, or seizures. Taking these substances in combination increases the likelihood of experiencing these side effects, and also increases the risk of serotonin syndrome.

If someone plans to take this substance, we recommend waiting until the results of further analysis are available. If you do choose to take this substance, start with a much lower dose than usual, and base this on dosing of Alpha D2PV as the more potent substance. Wait 60-90 minutes for the drug to take effect. Be aware of the high redose potential of these two drugs, and ideally avoid redosing as this is likely to result in the adverse effect described above. Avoid combining with other substances including alcohol. Make sure you or someone with you knows the signs of overdose, and if you experience any of the following symptoms, call 11 immediately and ask for help – you will not get in trouble and it could save a life: feeling extremely agitated or anxious, paranoid or manic, a very fast beating heart, tremors, convulsions, or seizures, suicidal thoughts.

For more information on synthetic cathinones click here.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz

Substance presumed to be: Clobromazolam

Date brought in for testing: Fourth week of August, 2024

Substances detected in the sample: Lidocaine, no psychoactive substances detected.

Our in-clinic testing methods were unable to identify a psychoactive substance in this sample, and it was sent to the laboratory for further analysis. Both sets of results identified this sample as consistent with lidocaine, with no psychoactive substances detected.

Just because our equipment didn't identify the drug that may be contained in this sample, does not mean there is no drug contained. There can always be something in the part of your substance we didn’t test. It also doesn’t mean that similar samples won’t contain a psychoactive substance – we recommend coming to get your new substances checked every time. If you choose to take an unidentified substance, we recommend taking extra care when trying it, in case a potent or large amount of drug is contained, or produces unpleasant or harmful effects. 

Clobromazolam is thought to be a particularly potent novel benzodiazepine. Little to no dosage information is available for this substance, however it is likely to be active at very low doses (thought to be up to 0.25 mg, possibly lower). 

There is no overdose reversal agent available for first-aid in case of benzodiazepine overdose (naloxone will not work for this drug class) - medical care is required to ensure someone stays safe and breathing after an overdose. This may look like: slurred speech, severe confusion, delusions, slowed, shallow or stopped breathing, blue fingertips or lips, loss of consciousness. Call 111 immediately to seek medical support. 

Overdose is much more likely if this drug is combined with other depressants: High or repeated doses of this substance, or combination with other benzodiazepines, opioids, dissociatives, fantasy-type (G/1,4-BD) drugs or alcohol greatly increases risks of vomiting, stopping breathing, or death.

For more information on staying safer when taking benzodiazepines click here and for more specific information about novel benzos click here. 

If this was your sample, you can return to the Drug Checking clinic you attended for additional advice to keep you and your community safer.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz

UPDATED RESULT:

Laboratory analysis has confirmed this sample was consistent with containing traces of Nitrazepam. 

Nitrazepam is a long-acting benzodiazepine with intermediate onset commonly used to treat panic disorders, severe anxiety, insomnia, and seizures. It also has sedative properties, as well as amnestic, anticonvulsant, and skeletal muscle relaxant effects. It can stay in someone’s system for 15-38 hours, even if they no longer feel the subjective effects.

We are unable to determine how much of the drug may be present in this sample. As the substance may not be evenly mixed, the relative proportions of each substance may be different each time. If someone does choose to take this substance, please read the advice in below and in the links provided. Take a smaller dose than may be indicated (e.g. a half or quarter dose), allow 45-60 minutes for the drug to take effect, and see how your body feels before taking more. Make sure you or someone you are with knows the signs to look out for in case of overdose.

INITIAL RESULT:

Substance presumed to be: Benzodiazepine (unspecified / inconclusive)

Date brought in for testing: Last week of August, 2024

Substances detected in the sample: Benzodiazepine (unspecified / inconclusive)

Due to the format of this sample were unable to conduct a full analysis in-clinic, and this sample is currently at the laboratory for further analysis. We'll update this result when results arrive back. If this was your sample, you can return to the Drug Checking clinic you attended to check whether we've heard back, and for additional advice to keep you and your community safer.

Our in-clinic testing indicated a positive strip-test result for a benzodiazepine, with negative strip-test results for nitazene and fentanyl. However, benzo strip-tests react with several benzodiazepines and cannot specify which of these is present. Equally, strip-tests do not detect all types of nitazenes, especially as new nitazenes entered the drug market regularly. We recommend waiting until the result of laboratory analysis are posted before taking this substance.

Overdose is much more likely if this drug is combined with other depressants: High or repeated doses of this substance, or combination with other benzodiazepines, opioids, dissociatives, fantasy-type (G/1,4-BD) drugs or alcohol greatly increases risks of vomiting, stopping breathing, or death.

There is no overdose reversal agent available for first-aid in case of benzodiazepine overdose (naloxone will not work for this drug class) - medical care is required to ensure someone stays safe and breathing after an overdose. This may look like: slurred speech, severe confusion, delusions, slowed, shallow or stopped breathing, blue fingertips or lips, loss of consciousness. Call 111 immediately to seek medical support. 

For more information on staying safer when taking benzodiazepines click here, and for more specific information about novel benzos click here. 

Contact: DISC Drug Checking team drugchecking@nznep.org.nz

UPDATED RESULT:

Laboratory analysis has confirmed this sample was consistent with containing traces of Bromazolam. 

Bromazolam is a novel benzodiazepine. Novel benzodiazepines, those that have entered the drug market relatively recently, are less well understood than prescription benzos or those that have been on the market for longer, such as alprazolam (Xanax). Dosing information is relatively untested and may be similar or lower than alprazolam, however there are indications that it may stay in your system for twice as long (more than 12 hours), even you no longer feel the effects. 

We are unable to determine how much of the drug may be present in this sample. As the substance may not be evenly mixed, the relative proportions of each substance may be different each time. If someone does choose to take this substance, please read the advice in below and in the links provided. Take a smaller dose than may be indicated (e.g. a half or quarter dose), allow 45-60 minutes for the drug to take effect, and see how your body feels before taking more. Make sure you or someone you are with knows the signs to look out for in case of overdose.

INITIAL RESULT:

Substance presumed to be: Bromazolam

Date brought in for testing: Last week of August, 2024

Substances detected in the sample: Benzodiazepine (unspecified / inconclusive)

Due to the format of this sample were unable to conduct a full analysis in-clinic, and this sample is currently at the laboratory for further analysis. We'll update this result when results arrive back. If this was your sample, you can return to the Drug Checking clinic you attended to check whether we've heard back, and for additional advice to keep you and your community safer.

Our in-clinic testing indicated a positive strip-test result for a benzodiazepine, with negative strip-test results for nitazene and fentanyl. However, benzo strip-tests react with several benzodiazepines and cannot specify which of these is present. Equally, strip-tests do not detect all types of nitazenes, especially as new nitazenes entered the drug market regularly. We recommend waiting until the result of laboratory analysis are posted before taking this substance.

Overdose is much more likely if this drug is combined with other depressants: High or repeated doses of this substance, or combination with other benzodiazepines, opioids, dissociatives, fantasy-type (G/1,4-BD) drugs or alcohol greatly increases risks of vomiting, stopping breathing, or death.

There is no overdose reversal agent available for first-aid in case of benzodiazepine overdose (naloxone will not work for this drug class) - medical care is required to ensure someone stays safe and breathing after an overdose. This may look like: slurred speech, severe confusion, delusions, slowed, shallow or stopped breathing, blue fingertips or lips, loss of consciousness. Call 111 immediately to seek medical support. 

For more information on staying safer when taking benzodiazepines click here and for more specific information about novel benzos click here.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz

Substance presumed to be: Methylone (bK-MDMA)

Date brought in for testing: Last week of August, 2024

Substances detected in the sample: Cyputylone (n-cyclohexylmethylone), MDMA

We identified the presence of cyputylone, a synthetic cathinone, and MDMA in this sample. We are unable to determine how much of each drug may be present in this sample.

Cyputylone and MDMA are both empathogens (drugs with promote empathy and pro-social behaviour) and stimulant class drugs. While MDMA is well understood, cyputylone is a novel cathinone and limited dosing information is available for this substance. As with most novel cathinones, it is likely that the dose range is much lower than for MDMA or more well characterised cathinones like methylone. Combining more than one stimulant is more stressful for your body, and creates greater risk of negative side effects, brain toxicity, and overdose. 

If someone chooses to take this substance, we recommend researching the substance carefully (including the links below), and taking only a very small amount first to see how it affects you. Wait at least 60-90 minutes before taking any more. As the substance may not be evenly mixed, the relative proportions of cyputylone and MDMA may be different each time, so consider this with your dosing. We recommend not taking it by yourself (have trusted friend(s) who can get help if needed), avoid mixing it with additional drugs, and watching for signs of stimulant overamping: Chest pain or severe heart palpitations, overheating, splitting headache, agitation / delirium, seizure and unconsciousness. If someone experiences concerning symptoms after taking this drug, phone 111 immediately to seek medical support. 

For more information on staying safer when taking cathinones, click here and MDMA, click here.

If this was your sample, you can return to the Drug Checking clinic you attended for additional advice to keep you and your community safer.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz 

Substance presumed to be: MDMA

Date brought in for testing: Third week of August, 2024

Substances detected in the sample: 3',4'-Methylenedioxy-N-tert-butylcathinone (tertylone/MDPT)

Both our in-clinic testing and further laboratory analysis confirmed the presence of Tertylone (aka MDPT) in this sample.

Tertylone is classified as a novel stimulant and substituted cathinone, structurally similar compounds include N-ethyl pentylone, pentylone, methylone, and butylone. Novel stimulants, those that have entered the drug market relatively recently, are less well understood than substances that have been on the market for longer. Accurate dosing information and the full range of effects (both short and long term) are unknown.

It is highly likely that Tertylone may produce some similar effects as other stimulants, which peak and wear off much sooner than MDMA. The side effects of these drugs are usually more intense than for MDMA, and can include being awake for multiple days, and intense anxiety and agitation. Cathinones can create a strong urge to re-dose (take more), which can very quickly cause someone to take too much and overdose. If you choose to take this substance, we recommend taking a lower dose (e.g. 1/10th of the amount you might take of MDMA), not using alone, or combining with other substances. If someone experiences concerning symptoms (chest pain, heart palpitations, delirium, seizure, unconsciousness) after taking this drug, call 111 immediately and seek medical support.

Click here for more information on about cathinones. 

Contact: DISC Drug Checking team [drugchecking@nznep.org.nz] 

Substance Presumed to be: Methamphetamine 

Date brought in for testing: 2nd week of July 

Substances detected in the sample: Levamisole

The only substance detected in this sample was levamisole. This is originally an anti-worming drug however this causes some nasty side effects. This does not produce a psychoactive effect.

Ingesting levamisole can seriously reduce your body's ability to fight off even minor infections.

People who snort, smoke, or inject drugs contaminated with levamisole can experience rapidly developing, life-threatening infections. If you develop any wound that will not heal or looks infected consult medical care without delay.  

Reminder to use sterile injecting equipment and use a wheel filter to remove germs to reduce the chance of infection. You can get these, clean needles and syringes, and advice to make your draw-up, preparation and shot safest, from our friends over at your local needle exchange outlet here.

If you choose to take a substance that might be this:

  
• Remember that this substance does not have any psychoactive effects.
• Lower doses are less risky. Start off with a small amount to check how it affects you. In general, swallowing a substance has a slower onset than other methods and means there might be more time to get medical help if needed.
• Avoid using it at the same time as other substances.
• Avoid using it alone. Have a buddy who can help, and call an ambulance, if things go wrong.
• Avoid taking more.

Contact info@knowyourstuff.nz for questions 

Substance presumed to be: Methamphetamine   

Date brought in for testing: First week of July, 2024

Substances detected in the sample: N-isopropylbenzylamine  - otherwise known as n-iso. No other psychoactive substances were detected in this sample.

N-iso has been used as a filler or substitute for methamphetamine, but is not known to have psychoactive effects in the sense of a high. People have reported effects from n-iso when smoked as sleepiness/drowsiness, dizziness, digestive issues (feeling gassy/bloated), depressive feelings, anxiety, skin issues such as pimples etc. When injected IV, people have reported intense burning sensations at usual methamphetamine-sized doses, soreness at site of injection, long lasting headaches, queasiness/nausea, bodily discomfort (aches/pains) and sleepiness/drowsiness.

We wrote an article last year with KnowYourStuffNZ explaining more about n-iso, and some of the other things we’ve seen going on with methamphetamine supply – have a read here: What's going on with our methamphetamine? – and feel free to return to the Drug Checking clinic you attended for more harm reduction information and advice. 

It’s worth noting that with these substances, misrepresentation can occur anywhere along the supply chain. We advise everyone to come and get their substances checked and not to assume that what you have is what you were told it is.

For further information and harm reduction advice, you can also click here for more information on staying safer when taking methamphetamine.  

Contact: DISC Drug Checking team drugchecking@nznep.org.nz 

UPDATED RESULT:

Laboratory analysis has confirmed this sample was consistent with containing cocaine and levamisole.

Levamisole is a cutting agent which is toxic to humans. High Alert have recently published an article on levamisole which we recommend you read here. 

Levamisole can lead to harm including fevers or chills, fatigue, and joint stiffness, inflammation and clotting of small blood vessels in the body, skin lesions and necrosis (tissue death), especially of the ears and nose, problems with bone marrow, such as agranulocytosis, a condition that supresses your immune system and weakens the body’s ability to fight off even lower-level infections. We recommend that you do not consume this substance as we cannot provide an accurate assessment of the relative amounts of cocaine and levamisole in this mixture. Harmful symptoms of levamisole use can appear days after consumption, so it is difficult to assess levels of harm at the time of consumption. Additionally, as these substances may not be evenly mixed, the relative proportions of cocaine and levamisole may be different each time.

If someone does choose to take this substance, take a smaller dose than may be indicated (e.g. a half or quarter dose), allow 30-60 minutes for the drug to take effect, and see how your body feels before taking more. If you start to experience symptoms that may be related to levamisole consumption (especially purple/black skin changes), see your doctor, or call Healthline (0800 611 116). Be honest about your drug use, it will help doctors give you the best treatment.

Please feel welcome to return to the Drug Checking clinic you attended for more information and advice.

INITIAL RESULT 

Substance presumed to be: Cocaine 

Date brought in for testing: Second week of July, 2024

Substances detected in the sample: Cocaine, potentially an amphetamine-type substance 

Our in-clinic testing results did identified that there may be another psychoactive substances in this sample, but we were unable to conclusively identify this and it has been sent to the laboratory for further analysis. We’ll update this result once we have the results of that analysis.

We recommend waiting until the result of further analysis are posted before taking this substance. If you choose to take an unidentified drug, we recommend taking extra care when trying it, in case a potent or large amount of drug is contained, or produces unpleasant or harmful effects. Have someone trusted around who can get help if something goes wrong – you won’t get in trouble with emergency services if you tell them you've used drugs.

Combining more than one stimulant is more stressful for your body, and creates greater risk of negative side effects and overdose (‘overamping’). We cannot provide an accurate assessment of the relative amounts of each substance if this is found to be a mixture. If someone does choose to take this substance, we advise taking a small amount first to see how it affects you. As the substance may not be evenly mixed, the relative proportions of each substance may be different each time, so consider this with your dosing.

For more information on staying safer when taking cocaine click here, and for information about amphetamines click  here and here. If this was your sample, you can return to the Drug Checking clinic you attended for additional advice to keep you and your community safer.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz 

UPDATED RESULT:

Laboratory analysis has confirmed this sample was consistent with containing MDMA with traces of ketamine.

Ketamine is a dissociative drug that acts as both a depressant and has some psychedelic effects. You can read more about ketamine here: Ketamine - The Level. 

Ketamine was detected in only trace amounts within this sample and we are unable to determine how much of each drug may be in this sample. It is possible that the presence of ketamine contributed to some unexpected effects from taking this sample. 

Mixing stimulants like MDMA and depressants like ketamine means that the two drugs can mask each other’s effects – so there can be a temptation to take more of the substance than planned. If one drug wears off more quickly, you can find yourself suddenly a lot more stimulated, or more sedated. Ketamine is a dissociative anaesthetic that worsens your coordination, which you may be less aware of while under the influence of MDMA, increasing risk of physical injury. Large doses of ketamine and MDMA together may create risk of serotonin syndrome, which can be fatal - especially if somebody is taking MAOI type anti-depressants.  

If someone plans to take this substance, start with a lower dose than usual and allow 45-90 minutes for the drug to take effect. Ideally avoid redosing, and if you do be aware of the different onset times of these two drugs. Depending on the route of administration, it is likely that ketamine will come on and wear off more quickly than MDMA. You can read more about this here:  Ketamine and MDMA.  Avoid combining with other substances including alcohol. 

If this was your sample, please fell welcome to return to the Drug Checking clinic you attended for additional advice to keep you and your community safer.

INITIAL RESULTS

Substance presumed to be: MDMA

Date brought in for testing: Second week of July, 2024

Substances detected in the sample: MDMA

Our in-clinic testing results did not identify any other psychoactive substances in this sample, but we were unable to conclusively rule out anything else and it has been sent to the laboratory for further analysis. We’ll update this result once we have the results of that analysis. 

MDMA is a stimulant and entactogen, and produces distinctive emotional and pro-social effects.

If unpleasant effects were experienced as a result of taking this sample, we recommend waiting until the result of further analysis are posted before taking more. However, if someone does choose to take this substance, we recommend starting with a lower dose than usual, allowing 45-90 minutes for the drug to take effect, and seeing how your body feels before taking more. Avoid combining with other substances including alcohol. 

Click here for more information on staying safer when taking MDMA. If this was your sample, you can return to the Drug Checking clinic you attended for additional advice to keep you and your community safer.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz 

UPDATED RESULT:

Laboratory analysis has confirmed this sample was consistent with containing MDMA with traces of ketamine and polyethylene (polythene).

Ketamine is a dissociative drug that acts as both a depressant and has some psychedelic effects. You can read more about ketamine here: Ketamine - The Level. Polythene is the most commonly produced plastic, commonly used for packaging material.

Ketamine was detected in only trace amounts within this sample and we are unable to determine how much of each drug may be in this sample. It is possible that the presence of ketamine contributed to some unexpected effects from taking this sample. 

Mixing stimulants like MDMA and depressants like ketamine means that the two drugs can mask each other’s effects – so there can be a temptation to take more of the substance than planned. If one drug wears off more quickly, you can find yourself suddenly a lot more stimulated, or more sedated. Ketamine is a dissociative anaesthetic that worsens your coordination, which you may be less aware of while under the influence of MDMA, increasing risk of physical injury. Large doses of ketamine and MDMA together may create risk of serotonin syndrome, which can be fatal - especially if somebody is taking MAOI type anti-depressants.  

If someone plans to take this substance, start with a lower dose than usual and allow 45-90 minutes for the drug to take effect. Ideally avoid redosing, and if you do be aware of the different onset times of these two drugs. Depending on the route of administration, it is likely that ketamine will come on and wear off more quickly than MDMA. You can read more about this here:  Ketamine and MDMA.  Avoid combining with other substances including alcohol. 

If this was your sample, please feel welcome to return to the Drug Checking clinic you attended for additional advice to keep you and your community safer.

INITIAL RESULTS 

Substance presumed to be: MDMA

Date brought in for testing: Second week of July, 2024

Substances detected in the sample: MDMA

Our in-clinic testing results did not identify any other psychoactive substances in this sample, but we were unable to conclusively rule out anything else and it has been sent to the laboratory for further analysis. We’ll update this result once we have the results of that analysis. 

MDMA is a stimulant and entactogen, and produces distinctive emotional and pro-social effects.

If unpleasant effects were experienced as a result of taking this sample, we recommend waiting until the result of further analysis are posted before taking more. However, if someone does choose to take this substance, we recommend starting with a lower dose than usual, allowing 45-90 minutes for the drug to take effect, and seeing how your body feels before taking more. Avoid combining with other substances including alcohol. 

Click here for more information on staying safer when taking MDMA. If this was your sample, you can return to the Drug Checking clinic you attended for additional advice to keep you and your community safer.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz 

Substance presumed to be: Ketamine

Date brought in for testing: Fourth week of July, 2024

Substances detected in the sample: MDMA

This sample was consistent with the presence of MDMA - no other drugs or filler were detected.

You can read more about MDMA and how to stay safer if you choose to take this substance here. 

Contact: DISC Drug Checking team drugchecking@nznep.org.nz

UPDATED RESULT:

Laboratory analysis found that this sample contains bromazolam with traces of methamphetamine.

Bromazolam is a novel benzodiazepine.  In addition to the information below, you can find more about staying safer when taking bromazolam and other novel benzos here: Bromazolam and other novel benzos - The Level.

Methamphetamine is a stimulant class drug. We detected very small amounts in the sample submitted for testing, and we are unable to say how much might be in the rest of this bag. For more information on staying safer when taking methamphetamine, click here: Methamphetamine - The Level

If someone does choose to take this substance, please read the advice in below and in the links provided. Take a smaller dose than may be indicated (e.g. a half or quarter dose), allow 30-60 minutes for the drug to take effect, and see how your body feels before taking more. Make sure you or someone you are with knows the signs to look out for in case of overdose.

If this was your sample, please feel welcome to return to the Drug Checking clinic you attended for more information and advice.

INITIAL RESULT: 

Substance presumed to be: Flualprazolam

Date brought in for testing: Fourth week of July, 2024

Substances detected in the sample: Possible presence of a benzodiazepine (results inconclusive).

Due to the format of this sample were unable to conduct a full analysis in-clinic, and this sample is currently at the laboratory for further analysis. We'll update this result when results arrive back. If this was your sample, you can return to the Drug Checking clinic you attended to check whether we've heard back, and for additional advice to keep you and your community safer.

Our in-clinic testing indicated a positive strip-test result for a benzodiazepine, with negative strip-test results for nitazene and fentanyl. However, benzo strip-tests cannot specify which of the benzodiazepine that they react with is present. Equally, strip-tests do not detect all types of nitazenes, especially as new nitazenes entered the drug market regularly. We recommend waiting until the result of laboratory analysis are posted before taking this substance.

Novel benzodiazepine, those that have entered the drug market relatively recently, are less well understood than prescription benzos or those that have been on the market for longer. Flualprazolam is structurally similar to alprazolam (Xanax), however accurate dosing information is not yet available and there are indications that it may stay in your system for twice as long (more than 12 hours), even you no longer feel the effects. 

Overdose is much more likely if this drug is combined with other depressants: High or repeated doses of this substance, or combination with other benzodiazepines, opioids, dissociatives, fantasy-type (G/1,4-BD) drugs or alcohol greatly increases risks of vomiting, stopping breathing, or death. 

There is no overdose reversal agent available for first-aid in case of benzodiazepine overdose (naloxone will not work for this drug class) - medical care is required to ensure someone stays safe and breathing after an overdose. This may look like: slurred speech, severe confusion, delusions, slowed, shallow or stopped breathing, blue fingertips or lips, loss of consciousness. Call 111 immediately to seek medical support.  

For more information on staying safer when taking benzodiazepines click here, and for more specific information about novel benzos click here. 

Contact: DISC Drug Checking team drugchecking@nznep.org.nz 

UPDATED RESULT

Laboratory analysis has confirmed this sample was consistent with containing Dimethyl sulfoxide (DMSO), desalkylquazepam and desalkylflurazepam.

DMSO is a chemical that dissolves many organic and inorganic substances and was the main component in this sample. While DMSO is used in topical prescription medicines to help them get through the skin, it can affect proteins, carbohydrates, fats, and water in the body. Our analyses indicate that the concentration of DMSO in this sample is very high. This concentration of DMSO is very likely to be toxic and to cause damage to cell membranes it comes into contact with. Contact with the skin may cause stinging and burning, and/or blistering in delicate areas such as the mouth or nose. Some non-prescription DMSO products are industrial grade. These aren't intended for human use and can contain impurities that can cause health issues. As DMSO is easily absorbed through the skin, it can carry these impurities into the body. DMSO can also cause damage to the liver and kidneys. Injecting DMSO by IV might cause red blood cells to break down, as red blood cell membranes cannot repair themselves. Avoid inhaling the vapor, as in concentrated amounts this may cause headache, dizziness, and sedation. 

Desalkylquazepam and desalkylflurazepam are a novel, long-lasting benzodiazepines. Desalkylflurazepam is a break down of desalkylquazepam, and it’s possible that this may have been produced in the analysis process – however we can’t know this for sure and it may be part of the original sample. Little to no dosage information is available for these substances, however they are likely to be active at very low doses (less than 1 mg, possibly much lower). 

If someone chooses to take this substance, we strongly recommend first diluting it 1 part sample to 9 parts of propylene glycol (PG, ideally use this) or water (if PG is not accessible) to reduce the harmful effects of DMSO. If using PG, the sample can be mixed all at once as a batch if preferred. If using water, we recommend doing this for each dose, as benzos can drop out of water more easily (possibly even if they’re dissolved in DMSO), and this may affect your dosing the next time round if done as a batch. Whichever dilutant is used (PG or water), make sure the solution is well mixed each time, and remember that even with doing this the amount of active substance may vary between each dose. Each time: Try a drop or two of the diluted substance on your tongue first, and wait to see if you notice any unusual sensations before taking any more – we recommend taking orally above other common routes of administration. Take a smaller dose than may be indicated (e.g. a half or quarter dose), allow 30-60 minutes for the drug to take effect, and see how your body feels before taking more. Please read the advice given below in addition to this advice and make sure you or someone you are with knows the signs to look out for in case of overdose.

If this was your sample, please feel welcome to return to the Drug Checking clinic you attended for additional advice to keep you and your community safer.

INITIAL RESULT 

Substance presumed to be: Diazepam (Valium)

Date brought in for testing: Last week of July, 2024

Substances detected in the sample: Possible presence of a benzodiazepine (results inconclusive).

Due to the format of this sample were unable to conduct a full analysis in-clinic, and this sample is currently at the laboratory for further analysis. We'll update this result when results arrive back. If this was your sample, you can return to the Drug Checking clinic you attended to check whether we've heard back, and for additional advice to keep you and your community safer.

Our in-clinic testing indicated a positive strip-test result for a benzodiazepine, with negative strip-test results for nitazene and fentanyl. However, benzo strip-tests cannot specify which of the benzodiazepine that they react with is present. Equally, strip-tests do not detect all types of nitazenes, especially as new nitazenes entered the drug market regularly. We recommend waiting until the result of laboratory analysis are posted before taking this substance. 

If someone does choose to take this substance, take a smaller dose than may be indicated (e.g. a half or quarter dose), allow 30-60 minutes for the drug to take effect, and see how your body feels before taking more. Only carry what you intend to use as benzos can have a high redose compulsion.

Take breaks from using benzos as tolerance and dependency can build fast. Do not stop using suddenly if you are dependent, it can cause seizures- dangerous potentially life threatening seizures.

Overdose is much more likely if this drug is combined with other depressants: High or repeated doses of this substance, or combination with other benzodiazepines, opioids, dissociatives, fantasy-type (G/1,4-BD) drugs or alcohol greatly increases risks of vomiting, stopping breathing, or death. 

There is no overdose reversal agent available for first-aid in case of benzodiazepine overdose (naloxone will not work for this drug class) - medical care is required to ensure someone stays safe and breathing after an overdose. This may look like: slurred speech, severe confusion, delusions, slowed, shallow or stopped breathing, blue fingertips or lips, loss of consciousness. Call 111 immediately to seek medical support.  

For more information on staying safer when taking benzodiazepines click here: Benzodiazepines - The Level and for more specific information about novel benzos click here: Bromazolam and other novel benzos - The Level

Contact: DISC Drug Checking team drugchecking@nznep.org.nz 

Substance presumed to be: GHB

Date brought in for testing: Fourth week of June, 2024

Substances detected in the sample: 1,4-BD

GHB and 1,4-BD are similar-feeling drugs with different dosages. Like GBL, 1,4-BD is turned into GHB in your body after you take it. Because of this, 1,4-BD may take longer to kick in and may last for longer. This means it may be easier to overdose on than GHB.

Click here for more information on staying safer when taking 1,4-BD - including important information on the differences in effects, onset times and dosing between GHB, GBL and 1,4-BD.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz

Substance presumed to be: Ketamine

Date brought in for testing: First week of June

Substances detected in the sample: 2-Fluoro-2-oxo PCE

2-Fluoro-2-Oxo-PCE (aka CanKet, 2F-NENDCK) is a ketamine analogue synthesised to be similar to the dissociative anaesthetic ketamine. Although structurally similar, ketamine analogues, such as 2-Fluoro-2-Oxo-PCE, can produce unexpected and unpredictable effects. In this case there is a delay of onset, a higher risk of and longer K-hole, Nausea, Visual disturbance and an overall longer duration.

If you do choose to take 2-Fluoro-2-Oxo-PCE, don’t use it alone, and don’t mix with other substances (especially depressant drugs like alcohol, opioids and the GHB/GBL family) and make sure you are in a safe environment.

A High Alert notification was recently published about this substance – please read this notification for more important information and ways to stay safer. 

Contact info@knowyourstuff.nz for questions 

UPDATED RESULT:

Laboratory analysis has confirmed this sample was consistent with containing ketamine and tadalafil (Cialis). 

Laboratory analysis did not detect bromazolam in this sample, however it’s always possible that small amounts of a substance can be present in the original batch/bag, but don’t make it into the sample that gets tested. In this case, it’s possible that the sample tested in clinic did contain a small amount of bromazolam, and the sample sent away for further analysis did not. 

If bromazolam is present within this sample, this is high risk in combination with ketamine. Overdose is much more likely if benzodiazepines are combined with other depressants, including dissociatives such as ketamine, other benzodiazepines, opioids, fantasy-type (G/1,4-BD) drugs or alcohol – or at high or repeated doses. Such combinations greatly increase risks of vomiting, stopping breathing, or death. There is no overdose reversal agent available for first-aid in case of benzodiazepine overdose (naloxone will not work for this drug class) - medical care is required to ensure someone stays safe and breathing after an overdose.

Combining tadalafil and ketamine may lead to increased side effects. Both ketamine and tadalafil increase likelihood of nausea/vomiting, confusion, dizziness/fainting, difficulty with moving, reduced sensitivity to touch, changes to heartrate, and urinary tract infections (UTI). 

We recommend that if someone intends taking this combination of substances, take a smaller dose than may be indicated (e.g. a half or quarter dose), allow 30-45 minutes for the drug to take effect, and see how your body feels before taking more. Ideally be in a safe, familiar environment and be aware that moving around on of this combination may be ill advised due to risk of physical injury. Stay hydrated and empty your bladder before sleeping to reduce the impact on your renal system. If you or anybody experiences slow/shallow/no breathing, or blue fingertips or lips after taking this substance, make sure someone phones 111 immediately to seek medical support. 

Click these links for more information on staying safer when taking tadalafil and ketamine. Information on bromazolam is provided in the original result below. 

Please feel welcome to return to the Drug Checking clinic you attended for more information and advice.

INITIAL RESULTS 

Substance presumed to be: Tadalafil (Cialis)

Date brought in for testing: Third week of June, 2024

Substances detected in the sample: Tadalafil (Cialis) and bromazolam

Our in-clinic testing results indicated that bromazolam was also contained in this sample, based on our FTIR analysis and benzo test strips. It has been sent to the laboratory for further analysis to confirm these initial results, and we’ll update this result once we have the results of that analysis. 

Tadalafil is a pharmaceutical drug that relaxes muscles of the blood vessels and increases blood flow to particular areas of the body, and is typically prescribed as a sexual aid. You can click here for more information on staying safer when taking tadalafil.

Bromazolam is a novel benzodiazepine – one that has entered the drug market relatively recently, and so it is less well understood than prescription benzos or those that have been on the market for longer. Bromazolam is active at lower doses than many other benzos, and can stay in your system for more than 12 hours, even you no longer feel the effects. Overdose is much more likely if this drug is combined with other depressants: High or repeated doses of this substance, or combination with other benzodiazepine, opioid, dissociative, fantasy-type (G/1,4-BD) drugs or alcohol greatly increases risks of vomiting, stopping breathing, or death.

We are unable to determine the amount of each drug contained in the sample. If someone chooses to take this substance, we recommend starting with a lower dose than may be indicated (e.g. a half or quarter dose), allowing 30-45 minutes for the drug to take effect, and seeing how your body feels before taking more. There is no overdose reversal agent available for first-aid in case of benzodiazepine overdose (naloxone will not work for this drug class) - medical care is required to ensure someone stays safe and breathing after an overdose. If you or anybody experiences slow / shallow / no breathing, or blue fingertips or lips after taking this substance, make sure someone phones 111 immediately to seek medical support. 

For more information on staying safer when taking benzodiazepines click here, and for specific information about bromazolam click here. 

If this was your sample, you can return to the Drug Checking clinic you attended for additional advice to keep you and your community safer.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz

Substance presumed to be: Gamma-hydroxybutyric acid (GHB)

Date brought in for testing: Third week of June, 2024

Substances detected in the sample: 1,4-butanediol (1,4-BD)

GHB and 1,4-BD are similar-feeling drugs, but it’s important to be aware that while these substances are similar, their dosages, onset times and subjective effects can be different. 1,4-BD is a GHB pro-drug – it is converted to GHB in the body. Because of that it can have a longer onset time and may not give the same type of high as GHB. This can sometimes lead people to take more before the full effects are felt, which can lead to overdosing. 

If someone chooses to take this substance, we recommend starting with a small dose, allowing 30-45 minutes for the drug to take effect, and seeing how your body feels. Wait at least 60-90 minutes before taking more. Overdose is much more likely if this drug is combined with other depressants: High or repeated doses of this substance, or combination with other fantasy-type (G/1,4-BD) drugs, benzodiazepine, opioids, dissociatives or alcohol greatly increases risks of vomiting, stopping breathing, or death.

Click here for more information on staying safer when taking GHB-type drugs including GBL and 1,4-BD. 

 Contact: DISC Drug Checking team drugchecking@nznep.org.nz

UPDATED RESULT:

Laboratory analysis has confirmed this sample was consistent with containing ketamine with traces of cocaine.

Harm reduction advice for these substances is provided in the initial result below, however please feel welcome to return to the Drug Checking clinic you attended for more information and advice.

INITIAL RESULT 

Substance presumed to be: Ketamine - preliminary

Date brought in for testing: Fourth week of June, 2024

Substances detected in the sample: Ketamine, possibly cocaine.

Our in-clinic testing results indicated that cocaine might be present in this sample, but we were unable to determine this conclusively and it has been sent to the laboratory for further analysis. We’ll update this result once we have the results of that analysis. 

Combining depressants (like ketamine) and stimulants (like cocaine) can lead to unexpected effects, and may mask the effects of each drug, which can suddenly be apparent if one wears off more quickly than the other. If someone chooses to take this substance, we recommend starting with a lower dose than may be indicated, allowing 30-45 minutes for the drug to take effect, and seeing how your body feels before taking more. We are unable to determine the amount of each drug contained in the sample, so if this is a mixture, the substances may not be evenly mixed, the relative proportions of ketamine and cocaine may be different each time, so consider this with your dosing. Ketamine is a dissociative anaesthetic that worsens your coordination, which you may be less aware of while under the influence of cocaine - moving around on of this combination may be ill advised due to risk of physical injury.

If this was your sample, you can return to the Drug Checking clinic you attended for additional advice to keep you and your community safer.

For more information on staying safer when taking these substances, click here: ketamine and cocaine. 

Contact: DISC Drug Checking team drugchecking@nznep.org.nz

Substance Presumed to be: Cocaine

Date brought in for testing:  3rd week of June 

Substances detected in the sample: No psychoactive detected- Update: an amino acid-type compound

Update 26/07/2024 Further analysis showed this to be an amino acid-type compound. Testing was unable to determine which one.

No psychoactive was detected in this sample. We suggest not consuming this substance. Standard harm reduction principles apply. 

Contact info@knowyourstuff.nz for questions 

Substance Presumed to be: Methamphetamine 

Date brought in for testing: 3rd Week of June

Substances detected in the sample: No psychoactive detected- update: Aluminium sulphate

Update 26/07/2024 Further analysis showed this to be aluminium sulphate. While this is generally considered non-toxic in low amounts it does cause irritation and local tissue damage when ingested, smoked or injected. We recommend not consuming this substance 

No psychoactive was detected in this sample. We suggest not consuming this substance. Standard harm reduction principles apply. 

Contact info@knowyourstuff.nz for questions 

Substance Presumed to be: Bromazolam

Date brought in for testing: First week of May

Substances detected in the sample: (Preliminary result) N-Desethyletonitazene

Please note: The final result for this sample is still being reviewed by the laboratory, and is subject to change. If this was your sample, you can return to the Drug Checking clinic you attended, for additional advice to keep you and your community safer. 

We did not detect diazepam in this sample. The only substance identified was desethyletonitazene, a very potent novel opioid drug. Desethyletonitazene may be up to 10 times as potent as fentanyl.

Fentanyl test strips will not detect the presence of a nitazene. You can now pre-order Nitazene testing strips from The Level. Different nitazenes can have dramatically different potencies, including when injected versus taken orally (can be exponentially more potent when taken intravenously). Nitazenes are associated with high degrees of harm in NZ, including hospitalisation and death. Both opioid-naïve and opioid-experienced clients are highly at risk of overdose or death from nitazenes. Volumetric dosing can be particularly challenging with nitazenes due to differences in solubility compared with other opioids, and is not necessarily an easy way to reduce risks when taking nitazenes. 

Opioid overdose is life-threatening and often fatal. If you choose to take this substance, know the signs of overdose: slow/shallow/no breathing, blue lips/fingertips, tiny / unresponsive pupils of the eye. We strongly recommend having naloxone (opioid overdose antidote) on hand – you can obtain a kit from your local Needle Exchange Provider . Multiple doses of naloxone may be required to reverse an overdose, and it may wear off before the effect of the opioid does, leading to recurrence of overdose. It is important to remain with a person who has overdosed after administering Naloxone to ensure they are ok and to provide support if overdose does reoccur. We strongly recommend having multiple naloxone ampoules or doses of Nyxoid (nasal spray) if you intend to take nitazenes, and strongly advise calling 111 for an ambulance in addition to naloxone administration if overdose occurs. 

Overdose and death and dramatically more likely in combination with other depressants: alcohol, opioids, benzodiazepines, dissociatives, G/1,4-BD. Especially, novel benzos with long half-lives (e.g. bromazolam) taken in the last few days are significantly more likely to contribute to overdose from nitazenes. Nitazenes should not be taken alone – a trusted friend who knows the dosage a person has taken, route of administration, other drugs consumed, signs of overdose and naloxone administration should be present to provide first aid and seek medical support if needed. You won’t get in trouble for calling an ambulance – they only want to ensure you are safe and breathing.

Contact info@knowyourstuff.nz for questions 

Substance presumed to be: MDMA

Date brought in for testing: Second week of May, 2024

Substances detected in the sample: Caffeine

Caffeine is a legal stimulant drug, which can cause wakefulness and euphoria, but also carries risk of side effects including anxiety. Some people can be allergic to caffeine, and in some combinations with other drugs, caffeine can increase your risk of side effects including brain toxicity. We recommend taking care and having a plan for if something goes wrong when taking caffeine with other drugs.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz or 0273150929

Substance presumed to be: Trenbolone enanthate

Date brought in for testing: Third week of May, 2024

Substances detected in the sample: Testosterone enanthate

This sample was consistent with containing testosterone enanthate. It's possible some Tren E might be contained as well, but our equipment did not detect it.

Trenbolone and testosterone are both growth hormones, but have different effects in our bodies. Testosterone is naturally produced and approved for use in humans, and is less potent than trenbolone, which does not naturally occur in humans. Testosterone can cause more fluid retention, although generally may have fewer side-effects than trenbolone. This difference in effects you may expect to feel is important to consider when starting a cycle, and self-monitoring throughout your cycle. 

If you choose to take this substance, we recommend making regular appointments to see a trusted clinician. Taking enough testosterone to feel the expected level of noticeable effects as if it were trenbolone, may lead to overloading on testosterone. Excess testosterone can turn into estrogen in the body, and you may want to take estrogen blockers to manage this. Steroids (particularly trenbolone) can increase your blood pressure, cholesterol (which can lead to heart disease or failure), or cause damage to your kidneys, liver, nerves and connective tissue. In all cases, a trusted medical professional can help to monitor your blood pressure and hormone levels. Drug Checking can't determine dosage contained in a vial, but regular check-ups and early detection can help you to change your dosing / steroid to reduce side effects, and make sure you get the gains you want while staying safer. 

Besides the specific drug contained, steroid solutions can always become contaminated by bacteria and mold in the air. After a steroid solution has been opened or exposed to air, we strongly recommend using a wheel filter to remove germs. If you're getting illicit / counterfeit steroids, they may already be non-sterile when you get them. Using a wheel filter is always recommended when you're not sure how a vial has been prepared. You can get these, clean needles and syringes, and advice to make your draw-up, preparation and shot safest, from your local needle exchange outlet at https://www.nznep.org.nz/outlets

You can find more information online at https://www.nznep.org.nz/resources

Steroids 

Filtering 

Injecting

Contact: DISC Drug Checking team drugchecking@nznep.org.nz or 0273150929

Substance presumed to be: Unknown

Date brought in for testing: Second week of May, 2024

Substances detected in the sample: Updated: Dimethylpentylone – no other drugs detected.

Please note: This sample is currently at the laboratory for analysis. We'll update this result when results arrive back. If this was your sample, you can return to the Drug Checking clinic you attended to check whether we've heard back, and for additional advice to keep you and your community safer. 

It's possible this sample contained two risky substances: Dimethylpentylone, and a novel drug (MD-valerophenone). Especially in combination, it is likely this sample could cause highly unexpected or dangerous effects. We recommend waiting until the result is available before choosing to take this substance. If you choose to take an unidentified drug, we recommend taking extra care when trying it, in case a potent or large amount of drug is contained. You can reduce some of your risk when taking an unknown substance by finely crushing, mixing, then swallowing only a quarter (or less) of a dose / pill, waiting 45-60 minutes to see how it affects your body, and having a trusted friend who can administer naloxone and / or call 111 for an ambulance immediately if anyone experiences concerning effects. 

UPDATED RESULT: Laboratory analysis has confirmed this sample was consistent with containing dimethylpentylone, with no other psychoactive drugs (including MDMA) detected.

Click here for more information on staying safer if you choose to take synthetic cathinones.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz

UPDATED RESULT:

Laboratory analysis has confirmed this sample was consistent with containing buprenorphine - no other psychoactive drugs were detected.

Buprenorphine is a prescription medicine and Class C controlled drug, used to treat opioid use disorder. Buprenorphine is an opioid partial agonist. It produces effects such as euphoria or respiratory depression at low to moderate doses. It may also cause side effects including constipation, headache, increased sweating, tiredness or drowsiness, loss of appetite, nausea and vomiting, abdominal pain, skin rashes, itching or hives. If someone chooses to take this substance, we recommend doing plenty of research, and consulting a medical professional to identify any risks, including interactions with other medications you may be taking.

Click here to read more important information about buprenorphine, its effects and side effects and ways to stay safer.

Please feel welcome to return to the Drug Checking clinic you attended for more harm reduction advice.

INITIAL RESULT:

Substance presumed to be: Unknown

Date brought in for testing: Second week of May, 2024

Substances detected in the sample: Inconclusive - awaiting laboratory result.  No fentanyl, benzodiazepine or nitazene detected.

Please note: This sample is currently at the laboratory for analysis. We'll update this result when results arrive back. If this was your sample, you can return to the Drug Checking clinic you attended to check whether we've heard back, and for additional advice to keep you and your community safer.

This sample was not able to be identified at the clinic it was presented to, however our tests indicated there is likely no fentanyl, benzodiazepine or nitazene type drugs contained. Strip tests aren't able to detect to those drugs 100% of times - it's important to consider those drugs (or new chemical analogues of them) are unlikely, but could still be present in a sample that has been checked, and make a plan for what to do if someone experiences an unexpected depressant overdose.

Just because our equipment didn't identify the drug that may be contained in this sample, does not mean there is no drug contained. If you choose to take an unidentified drug, we recommend taking care when trying it, in case a potent or large amount of drug is contained. You can reduce some of your risk when taking an unknown substance by finely crushing, mixing, then swallowing only a quarter (or less) of a dose / pill, waiting 45-60 minutes to see how it affects your body, and having a trusted friend who can administer naloxone and / or call 111 for an ambulance immediately if anyone experiences concerning effects.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz

UPDATED RESULT:

Laboratory analysis has confirmed this sample was consistent with containing buprenorphine - no other psychoactive drugs were detected.

Buprenorphine is a prescription medicine and Class C controlled drug, used to treat opioid use disorder. Buprenorphine is an opioid partial agonist. It produces effects such as euphoria or respiratory depression at low to moderate doses. It may also cause side effects including constipation, headache, increased sweating, tiredness or drowsiness, loss of appetite, nausea and vomiting, abdominal pain, skin rashes, itching or hives. If someone chooses to take this substance, we recommend doing plenty of research, and consulting a medical professional to identify any risks, including interactions with other medications you may be taking.

Click here to read more important information about buprenorphine, its effects and side effects and ways to stay safer.

Please feel welcome to return to the Drug Checking clinic you attended for more harm reduction advice.

INITIAL RESULT:

Substance presumed to be: Unknown

Date brought in for testing: Second week of May, 2024

Substances detected in the sample: Inconclusive - pending laboratory results.  No fentanyl, benzodiazepine or nitazene detected.

Please note: This sample is currently at the laboratory for analysis. We'll update this result when results arrive back. If this was your sample, you can return to the Drug Checking clinic you attended to check whether we've heard back, and for additional advice to keep you and your community safer.

This sample was not able to be identified at the clinic it was presented to, however our tests indicated there is likely no fentanyl, benzodiazepine or nitazene type drugs contained. Strip tests aren't able to detect to those drugs 100% of times - it's important to consider those drugs (or new chemical analogues of them) are unlikely, but could still be present in a sample that has been checked, and make a plan for what to do if someone experiences an unexpected depressant overdose.

Just because our equipment didn't identify the drug that may be contained in this sample, does not mean there is no drug contained. If you choose to take an unidentified drug, we recommend taking care when trying it, in case a potent or large amount of drug is contained. You can reduce some of your risk when taking an unknown substance by finely crushing, mixing, then swallowing only a quarter (or less) of a dose / pill, waiting 45-60 minutes to see how it affects your body, and having a trusted friend who can administer naloxone and / or call 111 for an ambulance immediately if anyone experiences concerning effects.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz

Substance presumed to be: Methamphetamine

Date brought in for testing: Second week of May, 2024

Substances detected in the sample: Methamphetamine, dimethyl sulfone (MSM)

This sample was consistent with the presence of methamphetamine, with dimethyl sulfone (MSM) added as a filler material. Dimethyl sulfone (MSM) is a relatively inert and harmless filler substance when taken in quantities up to several grams, and is generally regarded as safe for human consumption. We are unable to determine how much drug versus filler is contained in this sample. 

Click here for more information on staying safer when taking methamphetamine. 

Contact: DISC Drug Checking team drugchecking@nznep.org.nz or 0273150929

UPDATED RESULT:

Laboratory analysis has confirmed this sample was consistent with containing Benzylpiperazine (BZP) - no other psychoactive drugs were detected.

Harm reduction advice for this substance is provided in the initial result below, however please feel welcome to return to the Drug Checking clinic you attended for more information and advice.

INITIAL RESULT:

Substance presumed to be: Unknown

Date brought in for testing: Third week of May, 2024

Substances detected in the sample: Inconclusive - pending laboratory analysis.

Please note: This sample is currently at the laboratory for analysis. We'll update this result when results arrive back. If this was your sample, you can return to the Drug Checking clinic you attended to check whether we've heard back, and for additional advice to keep you and your community safer.

We are still waiting to hear back from the laboratory on this sample's contents - however we have seen a similar sample recently which matched this one closely. In that previous sample, laboratory analysis found the similar pill to contain both BZP and caffeine. It is possible this pill contents may be different, and we'll update this result as soon as more information is available.

BZP is a synthetic stimulant drug, producing effects similar to dexamphetamine, and side effects which can include nausea, anxiety, vomiting and heart palpitations. Psychosis, and worsening of existing mental health difficulties can also happen after taking BZP. There is very little information about the toxicity of BZP in humans. In repeated (over the course of a night) and high doses, BZP can cause uncontrolled muscle movements, seizures, and unconsciousness requiring hospital care. We recommend avoiding this substance if you have heart issues, seizure disorder, or a history of psychosis. Mixing BZP with other substances or taking high doses is most likely to produce highly unexpected or unpleasant effects. A typical dose of BZP can range between 50 mg and 100 mg (a tenth of a gram) when taken in known quantities - however it is not possible to measure how much drug was contained in this sample. BZP can take a while to take effect - up to two hours - which is worth considering before choosing to take more.

Caffeine is a legal stimulant drug, which can cause wakefulness and euphoria, but also carries risk of side effects including anxiety. Some people can be allergic to caffeine, and in some combinations with other drugs, caffeine can increase your risk of side effects including brain toxicity. We recommend taking care and having a plan for if something goes wrong when taking caffeine with other drugs.

We are unable to determine how much of each drug may be in this sample. Combining more than one stimulant is more stressful for your body, and creates greater risk of negative side effects and overdose. If someone chooses to take this substance, we recommend starting with a small dose (e.g. 1/4 of a pill dissolved in water), not taking it by yourself (have a trusted friend(s) who can get help if needed), avoid mixing it with additional drugs (including alcohol), and watching for signs of stimulant overamping: Chest pain or severe heart palpitations, overheating, splitting headache, agitation / delirium, seizure and unconsciousness. If someone experiences concerning symptoms after taking this drug, phone 111 immediately to seek medical support.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz

UPDATED RESULTS

Substance presumed to be: Ketamine

Date brought in for testing: Third week of May, 2024

Substances detected in the sample: Ketamine- No other drugs detected 

This substance was consistent with the presence of ketamine using our tools in-clinic and further laboratory testing. No other drugs or filler were detected. Effects of taking a substance can sometimes vary depending on set (mindset – how we are feeling) and setting (our surrounding environment). This can be especially the case with substances that have psychedelic or dissociative effects. Click here for more information on staying safer when taking ketamine.

UPDATED RESULT: Laboratory analysis confirmed this sample was consistent with containing ketamine - no other psychoactive drugs were detected. 

Contact: DISC Drug Checking team drugchecking@nznep.org.nz or 0273150929

UPDATED RESULT:

Laboratory analysis has confirmed this sample was consistent with containing 2-Fluoro-2-Oxo-PCE.

2-Fluoro-2-Oxo-PCE (aka CanKet, 2F-NENDCK) is a ketamine analogue synthesised to be similar to the dissociative anaesthetic ketamine. Although structurally similar, ketamine analogues, such as 2-Fluoro-2-Oxo-PCE, can produce unexpected and unpredictable effects. A High Alert notification was recently published about this substance – please read this notification for more important information and ways to stay safer. Please feel welcome to return to the Drug Checking clinic you attended for more harm reduction advice.

INITIAL RESULT:

Substance presumed to be: Ketamine

Date brought in for testing: Third week of May, 2024

Substances detected in the sample: Inconclusive ketamine analogue - pending laboratory analysis.

Please note: This sample is currently at the laboratory for analysis. We'll update this result when results arrive back. If this was your sample, you can return to the Drug Checking clinic you attended to check whether we've heard back, and for additional advice to keep you and your community safer.

This substance was not consistent with the presence of ketamine. Analogues (that is, chemicals where small parts of the structure have been altered) of ketamine are dissociative drugs as well, but often have different potencies and effects which can be very unexpected or unpleasant. The equivalent dose for a ketamine analogue will be different from the amount of ketamine you might normally take. The exact analogue of ketamine present in this sample hasn't been confirmed yet, however novel ketamine analogues are increasingly common and associated with harm in Australia and overseas. Generally speaking, people often find ketamine analogues to more intoxicating / stronger, but with effects which plateau earlier (meaning taking more doesn't give you more good effects). Visual disturbances, confusion, and hangover effects the next day can be more pronounced after taking analogues of ketamine.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz

UPDATED RESULT:

Laboratory analysis has confirmed this sample was consistent with containing a mixture ketamine and 2-Fluoro-2-Oxo-PCE.

2-Fluoro-2-Oxo-PCE (aka CanKet, 2F-NENDCK) is a ketamine analogue synthesised to be similar to the dissociative anaesthetic ketamine. Although structurally similar, ketamine analogues, such as 2-Fluoro-2-Oxo-PCE, can produce unexpected and unpredictable effects. A High Alert notification was recently published about this substance – please read this notification for more important information and ways to stay safer. Please feel welcome to return to the Drug Checking clinic you attended for more harm reduction advice.

INITIAL RESULT:

Substance presumed to be: Ketamine

Date brought in for testing: Third week of May, 2024

Substances detected in the sample: Inconclusive ketamine analogue - pending laboratory analysis.

Please note: This sample is currently at the laboratory for analysis. We'll update this result when results arrive back. If this was your sample, you can return to the Drug Checking clinic you attended to check whether we've heard back, and for additional advice to keep you and your community safer.

This substance was not consistent with the presence of ketamine. Analogues (that is, chemicals where small parts of the structure have been altered) of ketamine are dissociative drugs as well, but often have different potencies and effects which can be very unexpected or unpleasant. The equivalent dose for a ketamine analogue will be different from the amount of ketamine you might normally take. The exact analogue of ketamine present in this sample hasn't been confirmed yet, however novel ketamine analogues are increasingly common and associated with harm in Australia and overseas. Generally speaking, people often find ketamine analogues to more intoxicating / stronger, but with effects which plateau earlier (meaning taking more doesn't give you more good effects). Visual disturbances, confusion, and hangover effects the next day can be more pronounced after taking analogues of ketamine.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz

Substance presumed to be: Amphetamine

Date brought in for testing: Last week of May, 2024

Substances detected in the sample: Caffeine.

This sample was consistent with the presence of caffeine - no other drugs or filler were detected.

Caffeine is a legal stimulant drug, which can cause wakefulness and euphoria, but also carries risk of side effects including anxiety. Some people can be allergic to caffeine, and in some combinations with other drugs, caffeine can increase your risk of side effects including brain toxicity. We recommend taking care and having a plan for if something goes wrong when taking caffeine with other drugs.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz or 0273150929

Substance presumed to be: Methamphetamine

Date brought in for testing: Last week of May, 2024

Substances detected in the sample: Methamphetamine. 

This sample was consistent with the presence of methamphetamine - no other drugs or filler were detected.

Click here for more information on staying safer when taking methamphetamine.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz or 0273150929

UPDATED RESULT:

Laboratory analysis has confirmed this sample was consistent with containing 2-Fluoro-2-Oxo-PCE - no other psychoactive drugs were detected.

2-Fluoro-2-Oxo-PCE (aka CanKet, 2F-NENDCK) is a ketamine analogue synthesised to be similar to the dissociative anaesthetic ketamine. Although structurally similar, ketamine analogues, such as 2-Fluoro-2-Oxo-PCE, can produce unexpected and unpredictable effects. A High Alert notification was recently published about this substance – please read this notification for more important information and ways to stay safer. Please feel welcome to return to the Drug Checking clinic you attended for more harm reduction advice.

INITIAL RESULT:

Substance presumed to be: Ketamine

Date brought in for testing: Third week of May, 2024

Substances detected in the sample: Inconclusive ketamine analogue - pending laboratory analysis.

Please note: This sample is currently at the laboratory for analysis. We'll update this result when results arrive back. If this was your sample, you can return to the Drug Checking clinic you attended to check whether we've heard back, and for additional advice to keep you and your community safer.

This substance was not consistent with the presence of ketamine. Analogues (that is, chemicals where small parts of the structure have been altered) of ketamine are dissociative drugs as well, but often have different potencies and effects which can be very unexpected or unpleasant. The equivalent dose for a ketamine analogue will be different from the amount of ketamine you might normally take. The exact analogue of ketamine present in this sample hasn't been confirmed yet, however novel ketamine analogues are increasingly common and associated with harm in Australia and overseas. Generally speaking, people often find ketamine analogues to more intoxicating / stronger, but with effects which plateau earlier (meaning taking more doesn't give you more good effects). Visual disturbances, confusion, and hangover effects the next day can be more pronounced after taking analogues of ketamine.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz

Substance Presumed to be: Nandrolone phenylpropionate

Date Brought in for testing: Third week of May

Substances detected in the sample: Nandrolone decanoate (ester of nandrolone) + Trioctanoin + 2,3-Dioctanoyloxypropyl decanoate + Benzyl benzoate (lipids) 

If you choose to take this substance, we recommend making regular appointments to see a trusted clinician to confirm you are not overloading.

Steroids can increase your blood pressure, cholesterol (which can lead to heart disease or failure), or cause damage to your kidneys, liver, nerves and connective tissue. In all cases, a trusted medical professional can help to monitor your blood pressure and hormone levels. Drug Checking can't determine the dosage contained in a vial, but regular check-ups and early detection can help you change your dosing/steroid to reduce side effects and make sure you get the results you want while reducing your risks 

Steroid solutions can always become contaminated by bacteria and mould in the air. After a steroid solution has been opened or exposed to air, we strongly recommend using a wheel filter to remove germs. If you're getting illicit/counterfeit steroids, they may already be non-sterile when you get them. A wheel filter is always recommended when you're unsure how a vial has been prepared. You can get these, clean needles and syringes, and advice to make your draw-up, preparation and shot safest, from our friends over at your local needle exchange outlet at https://www.nznep.org.nz/outlets

Contact info@knowyourstuff.nz for questions 

Substance presumed to be: Diazepam

Date brought in for testing: First week of April, 2024

Substances detected in the sample: (Preliminary result) N-Desethyletonitazene

Please note: The final result for this sample is still being reviewed by the laboratory, and is subject to change. If this was your sample, you can return to the Drug Checking clinic you attended, for additional advice to keep you and your community safer. 

We did not detect any benzodiazepine in this sample. The only substance identified was desethyletonitazene, a very potent novel opioid drug. Desethyletonitazene may be up to 10 times as potent as fentanyl. Fentanyl test strips will not detect the presence of a nitazene. 

Different nitazenes can have dramatically different potencies, including when injected versus taking orally (can be exponentially more potent taken intravenously). Nitazenes are associated with high degrees of harm in NZ, including hospitalisation and death. Both opioid-naïve and opioid-experienced clients are highly at risk of overdose or death from nitazenes. Volumetric dosing can be particularly challenging with nitazenes due to differences in solubility compared with other opioids, and is not necessarily an easy way to reduce risks when taking nitazenes. 

Opioid overdose is life-threatening and often fatal. If you choose to take this substance, know the signs of overdose: slow/shallow/no breathing, blue lips/fingertips, tiny / unresponsive pupils of the eye. We strongly recommend having naloxone (opioid overdose antidote) on hand – you can obtain a kit from your local Needle Exchange Provider (https://www.nznep.org.nz/outlets). Multiple doses of naloxone may be required to reverse an overdose, and it may wear off before the effect of the opioid dose, leading to recurrence of overdose. It is important to remain with a person who has overdosed after administering Naloxone to ensure they are ok and to provide support if overdose does reoccur. We strongly recommend having multiple naloxone ampoules or doses of Nyxoid (nasal spray) if you intend to take nitazenes, and strongly advise calling 111 for an ambulance in addition to naloxone administration if overdose occurs. 

Overdose and death and dramatically more likely in combination with other depressants: alcohol, opioids, benzodiazepines, dissociatives, G/1,4-BD. Especially, novel benzos with long half-lives (e.g. bromazolam) taken in the last few days are significantly more likely to contribute to overdose from nitazenes. Nitazenes should not be taken alone – a trusted friend who knows the dosage a person has taken, route of administration, other drugs consumed, signs of overdose and naloxone administration should be present to provide first aid and seek medical support if needed. You won’t get in trouble for calling an ambulance – they only want to ensure you are safe and breathing.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz or 0273150929

Substance presumed to be: MDMA

Date brought in for testing: First week of April, 2024

Substances detected in the sample: MDMA

This sample was consistent with the presence of MDMA. We are unable to determine the amount of MDMA contained, however it is common for illicit pressed pills to contain multiple "doses" of MDMA in Aotearoa. A single dose of MDMA is typically approximately 80-120 mg (depending on your body), and it's not easy to tell how many doses have been put into one pill. You can sometimes tell by the scored marking on the back, the dose a pill is advertised as containing, or a Drug Checking clinic may be able to see signs that indicate multiple doses may be present. 

When MDMA pills contain multiple doses, it can be challenging to know how much to take, has been taken, or to predict the effects that a pill may cause. High doses of MDMA greatly increase the risk of side effects, and risk of interactions with other drugs or medications you may be taking.

The best way to stay safer when taking pills containing unknown amounts of MDMA is to crush a pill up finely, mix it well to ensure the drug contained is evenly distributed, and to divide the powder into sections (e.g. four or eight equal parts), then consume one of those parts and wait 30-45 minutes to see how it affects your body. If you experience any concerning side effects after taking this substance - especially uncontrolled temperature/shivering, agitation/paranoia, an abnormally fast heartbeat, or splitting headache - phone 111 immediately and seek medical support. 

Click here for more information on staying safer when taking MDMA. 

Contact: DISC Drug Checking team drugchecking@nznep.org.nz or 0273150929

Substance presumed to be: MDMA

Date brought in for testing: First week of April, 2024

Substances detected in the sample: Traces of ketamine, paracetamol, dimethyl sulfone (MSM)

We did not detect any MDMA in this sample. The psychoactive drug that was found in this sample – ketamine – was present only in traces that could be detected by the laboratory analysis. We are unable to determine how much ketamine may be present in this sample. 

We also detected paracetamol (a non-steroidal anti-inflammatory drug, commonly sold as Panadol) and a common filler dimethyl sulfone (abbreviation: MSM). Dimethyl sulfone is a relatively inert and harmless filler substance when taken in quantities up to several grams, and is generally regarded as safe for human consumption. Paracetamol can be harmful when taken in large quantities, and can cause liver damage and death if taken beyond the maximum recommended dosage (for adults: no more than 4 grams in 24 hours). 

If you choose to take this substance, we recommend avoiding combining it with alcohol, as it makes liver damage much more likely to occur. If you realise you’ve taken too much, or you experience a severe allergic reaction, unexpected abdominal pain, nausea, vomiting, diarrhoea, yellow skin/eyes or extreme confusion or sleepiness, call 111 immediately and seek medical support.

Click here for information on staying safer when taking ketamine. 

Contact: DISC Drug Checking team drugchecking@nznep.org.nz or 0273150929

Substance presumed to be: Novel benzodiazepine

Date brought in for testing: Third week of April, 2024

Substances detected in the sample: Benzodiazepine (unspecified)

This sample was unable to be conclusively identified at the drug checking clinic it was brought to, but did produce a positive reaction on a Benzodiazepine Test Strip – indicating the presence of a benzodiazepine drug. Different benzos (and especially novel ones, such as those with “flu” at the beginning of the name) can have very different effective dosages, and effects when taken. We recommend returning to the clinic you attended to submit a sample for further checking – this is a totally anonymous way to send a sample to a laboratory for a more specific identification of the drug contained. 

Broadly speaking, novel benzodiazepines often produce similar effects as better-known benzos, but can cause unexpectedly large side effects - particularly sedation (drowsiness) and amnesia (memory loss). Some of these novel benzos have a long "elimination half-life" or time until the drug clears your body. This means that even when you no longer feel affected by the drug, there may still be enough in your blood to make the effects of other drugs unexpectedly or unpredictably strong, which can cause someone to overdose. Even the next day after taking this drug, it is much easier to overdose from taking other substances: especially opioids, alcohol, ketamine, G/1,4-BD/Waz or additional benzo. 

In liquid form, it can be challenging to know how much of the drug you may have taken. Often the person selling it may have purchased or sold it as a different benzo, or may have mixed a different amount of drug / doses in than would be ideal. If someone chooses to take this substance, we recommend starting with a small amount first (e.g. a quarter of the amount of liquid the vendor has indicated as containing “one dose” for the presumed drug) and waiting an hour to see how it affects you, and having a trusted person nearby who can seek medical help if needed. If someone experiences concerning symptoms (especially slowed breathing / unconsciousness) after taking this drug, call 111 immediately and seek medical support.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz or 0273150929

Substance presumed to be: MDMA

Date brought in for testing: First week of April, 2024

Substances detected in the sample: Traces of ketamine, dimethyl sulfone (MSM), paracetamol

Please note: The result for this sample is a combination of in-clinic and laboratory checking results. Not all substances were detected by the laboratory, and are presented here as not conclusive, but likely enough to consider building into your risk reduction planning. Both reagents and the spectrometer we use gave good indication of the presence of paracetamol in addition to the drugs the laboratory found (trace ketamine and MSM). Drop back in to the Drug Checking clinic you attended, or get in touch with the team via email or phone for more information and advice around this specific result. 

This substance was consistent with the presence of trace amounts of ketamine, and two fillers: dimethylsulfone (MSM) and paracetamol. We are unable to determine the amount of drug contained in the sample or its purity. Dimethyl sulfone (MSM) is a relatively inert and harmless filler substance when taken in quantities up to several grams, and is generally regarded as safe for human consumption. Paracetamol can be harmful when taken in large quantities, and can cause liver damage and death if taken beyond the maximum recommended dosage (for adults: no more than 4 grams in 24 hours). 

Click here for more information on staying safer when taking ketamine.

Contact: DISC Drug Checking team drugchecking@nznep.org.nz or 0273150929

Substance presumed to be: Mixed psychoactives

Date brought in for testing: Last week of April, 2024

Substances detected in the sample: (Preliminary result) Ketamine, Nimetazepam, Caffeine, traces of methamphetamine

Please note: The final result for this sample is still being reviewed by the laboratory, and is subject to change. If this was your sample, you can return to the Drug Checking clinic you attended, for additional advice to keep you and your community safer. 

This substance was unable to be identified at the Drug Checking clinic - however laboratory analysis indicates 3 (plus a bit) psychoactive drugs may be present. We are unable to determine how much of each drug may be present, and recommend strong caution if you choose to take this substance. 

Ketamine is a dissociative anaesthetic commonly used both in medicine and recreation, which can cause effects including hallucinations, worsened coordination, and altered perception of reality. At higher doses, a phenomenon termed the ""K hole"" may be experienced, which can be alarming or hazardous if you aren't highly experienced and expecting it. It's essential to know how much of this drug you may have taken to stay safer when taking it, especially as ketamine's effects can be more strongly pronounced when taken in combination with other substances. 

Nimetazepam is a benzodiazepine drug, which can cause effects including sedation, reduction of anxiety, and at higher doses, there is a high risk of amnesia, very strange decision-making, and unconsciousness or death. Taken regularly, benzodiazepines can be highly addictive and dependence-causing. Stopping taking benzodiazepines suddenly can be dangerous once dependence develops - if you're concerned about stopping taking benzos, reach out to a trusted medical professional to find a safe way to stop taking these drugs. 

Caffeine is a legal stimulant drug, which can cause wakefulness and euphoria, but also carries risk of side effects including anxiety. In some combinations with other drugs, caffeine can increase your risk of side effects including brain toxicity. We recommend taking care and having a plan for if something goes wrong when taking caffeine with other drugs. 

Methamphetamine was also detected, although likely in small amounts. We are unable to determine the amount of any of the drugs contained in the sample, or their purity. 

The combination of these substances, and their unknown dosage, may produce dramatically unexpected effects and risk of overdose. In particular, the combination of ketamine and nimetazepam is likely to create risk of unconsciousness or stopping breathing. We strongly recommend avoiding taking this substance in high doses or in combination with other drugs. If you choose to take this substance, start with a very low dose (10 milligrams or less) and wait at least an hour to see how it affects you, and have a trusted friend with you who can get medical help if needed. 

Contact: DISC Drug Checking team drugchecking@nznep.org.nz or 0273150929

Substance presumed to be: Ketamine

Date brought in for testing: Last week of April, 2024

Substances detected in the sample: Ketamine - no other drugs detected.

Laboratory analysis confirmed this sample was consistent with containing ketamine - no other psychoactive drugs were detected. 

Click here for more information on staying safer when taking ketamine. 

Contact: DISC Drug Checking team drugchecking@nznep.org.nz